Ceftaroline in severe community-acquired pneumonia.
Rev Esp Quimioter
; 35 Suppl 1: 28-30, 2022 Apr.
Article
en En
| MEDLINE
| ID: mdl-35488821
ABSTRACT
Severe community-acquired pneumonia (SCAP) is associated with high mortality. Factor such as early adequate antibiotic therapy, delay in intensive care unit (ICU) care and pneumonia caused by resistant pathogens are associated with worse outcomes in SCAP patients. Ceftaroline is a fifth-generation cephalosporin with bactericidal activity against Gram-positive pathogens (including methicillin-resistant Staphylococcus aureus [MRSA] and multidrug-resistant Streptococcus pneumoniae) and common Gram-negative organisms. The efficacy and safety for the treatment of pneumonia was evaluated in three randomized control trials were ceftaroline demonstrated superiority against ceftriaxone for the treatment of pneumonia in hospitalized patients with Pneumonia Severity Index (PSI) III - IV.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neumonía
/
Infecciones Comunitarias Adquiridas
/
Staphylococcus aureus Resistente a Meticilina
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Rev Esp Quimioter
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2022
Tipo del documento:
Article
País de afiliación:
España